Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_2
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (66.7%)
Phase 41 (33.3%)

Trials by Status

completed350%
unknown117%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_4

Fycompa in Catamenial Epilepsy

NCT05201703
completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

NCT03059381
completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

NCT03059329
terminatedphase_2

Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients

NCT03377309
completed

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

NCT03208660
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05201703Phase 4

Fycompa in Catamenial Epilepsy

Terminated
NCT03059381

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Completed
NCT03059329

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

Completed
NCT03377309Phase 2

Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients

Terminated
NCT03208660

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Completed
NCT02511873Phase 2

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6